paclitaxel/encequidar (Pending FDA Approval)

Brand and Other Names:Oraxol
  • Print
Sections

Dosing & Uses

Metastatic Breast Cancer

Pending FDA approval for metastatic breast cancer

Next:

Pharmacology

Mechanism of Action

Paclitaxel: Supports microtubule assembly by enhancing action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication; additionally, the drug can distort mitotic spindles, resulting in the chromosome breakage; may also suppress cell proliferation and modulate immune response

Encequidar: Binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.